|Bid||57.01 x 200|
|Ask||58.98 x 200|
|Day's Range||57.34 - 57.56|
|52 Week Range||49.05 - 61.17|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.11%|
Localized geopolitical risks like the tension in the Middle East are unlikely to cause substantial damage to the markets in the long run, though they could bolster oil prices in the short term. The tension in the Korean Peninsula could be the biggest danger to market stability in the long run. As long as the balance is maintained between US interests and North Korea’s ambitions, the status quo is likely to prevail.
What Triggered the Stock Market Panic This Month? The last two trading sessions on February 2 and 5 have left many investors worried about assets in the bond (BND) and stock markets. The sell-off in the stock market began after the US employment report was published on Friday, February 2.
In 3Q17, dolutegravir franchise drugs Triumeq and Tivicay were major drivers of GlaxoSmithKline’s (GSK) rising HIV portfolio revenues. Triumeq and Tivicay are marketed by ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer (PFE), and Shinogi. At the end of 3Q17, GlaxoSmithKline had estimated the overall market share of dolutegravir-based regimens to be around 26% in the US, higher than the 23% market share measured at the beginning of 2017.
In 3Q17, GlaxoSmithKline (GSK) reported global sales close to 7.8 billion pounds, which is a year-over-year (or YoY) rise of 2% on a constant exchange rate (or CER) basis and 4% YoY growth on an actual exchange rate (or AER) basis. The company reported earnings per share (or EPS) close to 24.8 pounds in 3Q17, which is a YoY rise of 46% on a CER basis and 49% on an AER basis. GlaxoSmithKline also reported adjusted EPS close to 32.5 pounds in 3Q17 and expects to witness a 3% to 5% YoY rise in adjusted EPS for 2017.
In January 2018, the U.S. FDA (Food and Drug Administration) accepted Novartis’s (NVS) supplemental biologics license application (or SBLA) for Kymriah suspension for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL) who are not candidates for autologous stem cell transplant (or ASCT). The U.S. FDA granted Novartis’s sBLA for priority review. Also, the European Medicines Agency (or EMA) granted accelerated assessment to the marketing authorization application (or MAA) for Novartis’s Kymriah for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (or ALL) and also for adults with relapsed or refractory DLBCL who are not candidates for ASCT.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As we saw in the previous part of this series, Teva Pharmaceutical Industries (TEVA) is determined to pay down a considerable amount of its debt totaling $32 billion over the next few years. The company aims to achieve financial stability through improvement in operating profits and stable cash flow generation over the next few years.
This article is a part of InvestorPlace’s Best ETFs for 2018 contest. TJeff Reeves’ pick for the contest is the Vanguard FTSE All World Ex-U.S. Small Cap ETF (NYSEARCA:VSS). After all, the big headlines last year always seemed to be talking about President Donald Trump, or the broad-based rally in stocks or sometimes the two at the same time.
Investors are widely embracing low-fee international exchange traded funds in 2017. With international equities outpacing U.S. stocks and luring U.S. investors in the process, investors would do well to ...
There have been few changes since we first began issuing Morningstar Analyst Ratings for ETFs one year ago, but we've ramped up coverage dramatically.
With international equities outpacing U.S. stocks and luring U.S. investors in the process, investors would do well to remember one of the largest ex-US exchange traded funds: The Vanguard Total International ...
In 1H17, Novartis's (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis.
GlaxoSmithKline (GSK) added new products and improved the supply chain for consumer healthcare products in the last few years.